Cost-effectiveness of moderate-to-severe psoriasis treatment

Bibliography

• KOO J: Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol. Clin. (1996) 14(3):485-496.
   PubMed Web of Science ®Google Scholar
• CHRISTOPHERS E: Psoriasis-epidemiology and clinical spectrum. Clin. Exp. Dermatol. (2001) 26(4):314-320.
   PubMed Web of Science ®Google Scholar
• RAPP SR, FELDMAN SR, EXUM ML, FLEISCHER AB JR, REBOUSSIN DM: Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. (1999) 41(3):401-407.
   PubMed Web of Science ®Google Scholar
• FELDMAN SR: The psoriasis and psoriatic arthritis pocket guide: treatment algorithms and management options. National Psoriasis Foundation, Portland, Ore (2005):57-59.
   Google Scholar
• LIEM WH, MCCULLOUGH JL, WEINSTEIN GD: Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis (1995) 55(5):306-310.
   PubMed Web of Science ®Google Scholar
• KRUEGER G, KOO J, LEBWOHL M et al.: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. (2001) 137(3):280-284.
   PubMed Web of Science ®Google Scholar
• STERN RS, NIJSTEN T, FELDMAN SR, MARGOLIS DJ, ROLSTAD T: Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J. Investig. Dermatol. (2004) 9(2):136-139.
   Web of Science ®Google Scholar
• SANDER HM, MORRIS LF, PHILLIPS CM, HARRISON PE, MENTER A: The annual cost of psoriasis. J. Am. Acad. Dermatol. (1993) 28(3):422-425.
   PubMed Web of Science ®Google Scholar
• FELDMAN SR, FLEISCHER AB, JR., REBOUSSIN DM et al.: The economic impact of psoriasis increases with psoriasis severity. J. Am. Acad. Dermatol. (1997) 37(4):564-569.
   PubMed Web of Science ®Google Scholar
• FELDMAN SR, GARTON R, AVERETT W, BALKRISHNAN R, VALLEE J: Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin. Pharmacother. (2003) 4(9):1525-1533.
   PubMed Web of Science ®Google Scholar
• KRUTMANN J: Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)therapy. J. Photochem. Photobiol. (1998) 44(2):159-164.
   Web of Science ®Google Scholar
• PITTELKOW MR, PERRY HO, MULLER SA, MAUGHAN WZ: Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study. Arch. Dermatol. (1981) 117(8):465-468.
   PubMed Web of Science ®Google Scholar
• COVEN TR, BURACK LH, GILLEAUDEAU R et al.: Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch. Dermatol. (1997) 133(12):1514-1522.
   PubMed Web of Science ®Google Scholar
• ASHCROFT DM, LI WAN PO A, GRIFFITHS CE: Therapeutic strategies for psoriasis. J. Clin. Pharm. Therapeut. (2000) 25(1):1-10.
   PubMed Web of Science ®Google Scholar
• GORDON PM, DIFFEY BL, MATTHEWS JN, FARR PM: A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J. Am. Acad. Dermatol. (1999) 41(5):728-732.
   PubMed Web of Science ®Google Scholar
• STERN RS, NICHOLS KT, VAKEVA LH: Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N. Engl. J. Med. (1997) 336(15):1041-1045.
   PubMed Web of Science ®Google Scholar
• STERN RS, LAIRD N, MELSKI J et al.: Cutaneous squamous-cell carcinoma in patients treated with PUVA. N. Engl. J. Med. (1984) 310(8):1156-1161.
   PubMed Web of Science ®Google Scholar
• LINDELOF B, SIGURGEIRSSON B, TEGNER E et al.: PUVA and cancer: a large-scale epidemiological study. Lancet (1991) 338(8759):91-93.
   PubMed Web of Science ®Google Scholar
• STERN RS, BAGHERI S, NICHOLS K, STUDY PFU: The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J. Am. Acad. Dermatol. (2002) 47(1):33-39.
   PubMed Web of Science ®Google Scholar
• ROENIGK HH JR, AUERBACH R, MAIBACH H, WEINSTEIN G, LEBWOHL M: Methotrexate in psoriasis: consensus conference. J. Am. Acad. Dermatol. (1998) 38(3):478-485.
   PubMed Web of Science ®Google Scholar
• HEYDENDAEL VM, SPULS PI, OPMEER BC et al.: Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N. Engl. J. Med. (2003) 349(7):658-665.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS CE, CLARK CM, CHALMERS RJ, LI WAN PO A, WILLIAMS HC: A systematic review of treatments for severe psoriasis. Health Tech. Assess. (2000) 4(40):1-125.
   PubMedGoogle Scholar
• HO VC, GRIFFITHS CE, BERTH-JONES J et al.: Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J. Am. Acad. Dermatol. (2000) 44(4):643-651.
   Web of Science ®Google Scholar
• Biogen, Inc.: Amevive® (alefacept) prescribing information. Biogen Inc., Cambridge (MA) USA (2005).
   Google Scholar
• ORTONNE JP: Clinical response to alefacept: results of a Phase III study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. (2003) 17(S2):12-16.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M, CHRISTOPHERS E, LANGLEY R et al.: An international, randomized, double-blind, placebo-controlled Phase III trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol. (2003) 139(6):719-727.
   PubMed Web of Science ®Google Scholar
• GORDON K: Efficacy and safety of multiple courses of alefacept in combination with other psoriasis therapies. Proceedings of the 63rd Annual Meeting of the American Academy of Dermatology. New Orleans, LA (February 2005).
   Google Scholar
• MENTER A: Long-term use of alefacept: Efficacy in patients who have received multiple courses of therapy. Proceedings of the 63rd Annual Meeting of the American Academy of Dermatology. New Orleans, LA (February 2005).
   Google Scholar
• GOFFE BS: Long-term safety of alefacept in patients who have received up to nine courses of therapy. Proceedings of the 63rd Annual Meeting of the American Academy of Dermatology. New Orleans, LA (February 2005).
   Google Scholar
• JULLIEN D, PRINZ JC, LANGLEY RG et al.: T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology (2004) 208:297-306.
   Google Scholar
• GOTTLIEB AB: Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: final Phase IIIb study results. J. Am. Acad. Dermatol. (2005) 52(3):1.
   Web of Science ®Google Scholar
• GOTTLIEB AB, GORDON KB, LEBWOHL MG et al.: Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J. Drugs Dermatol. (2004) 3(6):614-624.
   PubMedGoogle Scholar
• LEBWOHL M, TYRING SK, HAMILTON TK et al.: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. (2003) 349(21):2004-2013.
   PubMed Web of Science ®Google Scholar
• MENTER A, GORDON K, CAREY W et al.: Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch. Dermatol. (2005) 141(1):31-38.
   PubMed Web of Science ®Google Scholar
• LEONARDI CL, PAPP KA, GORDON KB et al.: Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized Phase III trial. J. Am. Acad. Dermatol. (2005) 52(3):425-433.
   PubMed Web of Science ®Google Scholar
• MENTER A: Safety and tolerability of efalizumab therapy for patients with moderate to severe chronic plaque psoriasis: results of an open-label Phase IIIb multicenter trial. Proceedings of the 63rd Annual Meeting of the American Academy of Dermatology. New Orleans, LA (February 2005).
   Google Scholar
• LEONARDI CL, POWERS JL, MATHESON RT et al.: Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. (2003) 349(21):2014-2022.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M: Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis. Proceedings of the 63rd Annual Meeting of the American Academy of Dermatology. New Orleans, LA (February 2005).
   Google Scholar
• Immunex Corporation: Enbrel® (etanercept) prescribing information. Immunex Corporation, Thousand Oaks (CA) USA (2005).
   Google Scholar
• GOTTLIEB AB, EVANS R, LI S et al.: Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. (2004) 51(4):534-542.
   PubMed Web of Science ®Google Scholar
• MAHIQUES SANTOS L, MARTINEZ-MENCHON T, SANCHEZ CARAZO JL et al.: Treatment of severe refractory psoriasis with infliximab. Med. Clin. (2004) 123(17):657-658.
   PubMed Web of Science ®Google Scholar
• ANTONI CE: IMPACT and IMPACT 2: Consistent skin response to infliximab across studies in patients with psoriatic arthritis. Proceedings of the 63rd Annual Meeting of the American Academy of Dermatology. New Orleans, LA (February 2005).
   Google Scholar
• Centocor, Inc.: Remicade® (infliximab) prescribing information. Centocor, Inc. Malvern (PA), USA (2005).
   Google Scholar
• LANGLEY R: Long-term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis. Proceedings of the 63rd Annual Meeting of the American Academy of Dermatology. New Orleans, LA (February 2005).
   Google Scholar
• LEONARDI CL: Experience with anti-TNF therapies in psoriatic diseases [symposium]. Proceedings of the 29th Annual Hawaii Dermatology Seminar. Maui, Hawaii (March 2005).
   Google Scholar
• SCHIFF M: Safety and efficacy of more than 4 years of adalimumab therapy in rheumatoid arthritis. Proceedings of the 63rd Annual Meeting of the American Academy of Dermatology. New Orleans, LA (February 2005).
   Google Scholar
• Abbott Laboratories: Humira® (adalimumab) prescribing information. Abbot Laboratories, North Chicago (IL) USA (2005).
   Google Scholar
• KOO J, LEBWOHL M: Duration of remission of psoriasis therapies. J. Am. Acad. Dermatol. (1999) 44(1):51-59.
   Google Scholar
• HANKIN CS, FELDMAN SR, SZCZOTKA A, STINGER SC, FISH L, HANKIN DL: A cost comparison of treatments for moderate to severe psoriasis. Drug Ben.Trends (2005) 17(5):200-214.
   Google Scholar
• ZACHARIAE H: Have methotrexate-induced liver fibrosis and cirrhosis become rare? Dermatology (2005) 211:307-308.
   PubMed Web of Science ®Google Scholar
• CALLEN JP, KRUEGER GG, LEBWOHL M et al.: AAD consensus statement on psoriasis therapies. J. Am. Acad. Dermatol. (2003) 49(5):897-899.
   PubMed Web of Science ®Google Scholar
• GUENTHER L LR, SHEAR NH et al.: Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian psoriasis expert panel. J. Cut. Med. Surg. (2004) 8(5):321-337.
   PubMed Web of Science ®Google Scholar
• STERRY W, BARKER J, BOEHNCKE WH et al.: Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br. J. Dermatol. (2004) 151(S69):3-17.
   PubMed Web of Science ®Google Scholar
• KRUEGER GG, FELDMAN SR, CAMISA C et al.: Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J. Am. Acad. Dermatol. (2000) 43(2):281-285.
   Google Scholar
• FELDMAN SR: A quantitative definition of severe psoriasis for use in clinical trials. J. Dermatol. Treat. (2004) 15(1):27-29.
   PubMedGoogle Scholar
• TRAVIS L, WEINBERG JM: Medical backgrounder: psoriasis. Drugs of Today (2002) 38(12):847-865.
   PubMed Web of Science ®Google Scholar
• HOUSMAN TS, ROHRBACK JM, FLEISCHER AB JR, FELDMAN SR: Phototherapy utilization for psoriasis is declining in the United States. J. Am. Acad. Dermatol. (2002) 46(4):557-559.
   PubMed Web of Science ®Google Scholar